Nikolaos Chalkias

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.